Immune profile differs during symptom flare for patients with irritable bowel syndrome
Interferon- concentrations and THELPER cells are significantly reduced during symptom flares.
Irritable Bowel Syndrome
Irritable bowel syndrome medication linked to pancreatitis in certain patients
The FDA has received 120 reports of serious cases of pancreatitis or death after the approval of Viberzi in May 2015.
Patients diagnosed with upper functional gastroenterology disorders often have irritable bowel syndrome
The risk factors for IBS-FD overlap deserve more concern, according to the authors.
FDA approves two new therapies for irritable bowel syndrome
Two new therapies to treat irritable bowel syndrome, eluxadoline and rifaximin, have been approved by the FDA.
New guidelines address irritable bowel syndrome drugs
New guidelines for irritable bowel syndrome treatment have been released by the American Gastroenterological Association.
Yoga may ease inflammatory bowel disease
Trends observed toward improvement in health-related quality of life and self-efficacy in children.
Activated charcoal for poison control
Activated charcoal is a relatively benign product with a low risk profile.
Celiac disease more common with IBS
Classifying abdominal pain-related disorders can help determine which patients with IBS should be screened for celiac disease.
FDA approves Linzess for IBS, chronic constipation
Linzess sanctioned for constipation that does not respond to conventional treatment.
Choosing the best inflammation marker
Which serologic measure of inflammation is the most cost-effective and reliable when monitoring inflammatory disease?
